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1607-551X/Copyright ª 2015, KaohsiuAbstract Microtubules are an ideal target for anticancer drugs because of their essential role
in mitosis. Colchicine is a microtubule destabilizer. Whether the clinically acceptable colchi-
cine concentrations had anticancer effects on human cholangiocarcinoma cells was investi-
gated. Two human cholangiocarcinoma cell lines (C14/KMUH, C51/KMUH) were investigated
using clinically acceptable plasma colchicine concentrations (2 ng/mL and 6 ng/mL for the
in vitro experiment, 0.07 mg colchicine/kg/d  14 days for the nude mouse experiment).
Our results showed that colchicine caused significantly dose-dependent antiproliferative ef-
fects on both cell lines (all p < 0.0001). Nude mouse (BALB/c-nu) experiments showed that
the increased tumor volume ratios in colchicine-treated mice were significantly lower than
control mice started from the 11th day of treatment (p Z 0.0167). The tumor growth rates
in colchicine-treated mice after 14 days of treatment were significantly lower than in control
mice (0.147  0.004/d vs. 0.274  0.003/d, pZ 0.0015). In addition to the well-known direct
colchicineetubulin interaction as a common anticancer mechanism of colchicine, microarray
and quantitative reverse transcriptase-polymerase chain reaction showed that the antiproli-
ferative effects of both 2 ng/mL and 6 ng/mL colchicine on C14/KMUH cells could be partially
explained by downregulations of both HSD11B2 and MT-COI. There was no effect of colchicineeclare no conflicts of interest.
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230 C.-C. Wu et al.on MT-COI expression in C51/KMUH cells, however, 6 ng/mL colchicine also downregulated
HSD11B2 in this cell line. In conclusion, clinically acceptable colchicine concentrations can
inhibit the proliferation of human cholangiocarcinoma cells. This drug has good potential for
the palliative treatment of cholangiocarcinoma due to its low cost and our long-standing pre-
scription experience.
Copyright ª 2015, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Cholangiocarcinoma (CC) is one of the most difficult-to-
treat intra-abdominal malignancies. Although surgical
resection of the tumor and liver transplantation may pro-
vide the opportunity for long-term survival, these modal-
ities can only be applied in a small number of patients [1].
For patients unable to receive a surgical approach, several
palliative treatments including radiotherapy, chemo-
therapy, and photodynamic therapy have been applied but
the effects were limited [2].
The common characteristic of cancer cells is increased
rate of mitosis, which means that cancer cells are more
vulnerable to mitotic poison than are normal cells. Micro-
tubules have long been considered as an ideal target for
anticancer drugs because of their essential roles in mitosis
and forming the dynamic spindle apparatus. Colchicine is a
cheap alkaloid agent that has been used in medicine for a
very long time [3e5]. It is a microtubule destabilizer that
has a very strong binding capacity to tubulin to perturb the
assembly dynamics of microtubules [6e9]. It also can in-
crease cellular free tubulin to limit mitochondrial meta-
bolism in cancer cells through inhibition of the voltage-
dependent anion channels of the mitochondrial mem-
brane [10]. The cost of colchicine is much more affordable
than other microtubule-interfering agents such as pacli-
taxel and docetaxel. Moreover, oral intake of colchicine is
a very convenient and safe treatment when it is appropri-
ately used and contraindications have been excluded
[3e5]. The peak plasma concentrations after oral admin-
istration of 0.6e1 mg colchicine range from approximately
2 ng/mL to 6 ng/mL [11e13]. The lowest reported lethal
doses of oral colchicine are 7e26 mg and acute ingestions
of colchicine exceeding 0.5 mg/kg have a high fatality rate
[5]. Our recent in vitro and in vivo experiments showed
that the clinically acceptable colchicine concentrations
had significantly dose-dependent anticancer effects on
hepatocellular carcinoma (HCC) cells [14]. The anticancer
effects of colchicine on HCC cells originated not only from
the well-known direct colchicineetubulin interaction
[6e10] but also from colchicine-induced differential ex-
pressions of several antiproliferative genes [14]. Whether
the clinically acceptable colchicine concentrations also had
significant anticancer effects on CC cells is still unknown.
This study was done to clarify this issue for the investiga-
tion of the potential role of colchicine in the palliative
treatment of CC. All gene names are according to the
official symbols from the HUGO Gene Nomenclature Com-
mittee provided by the US National Center for Biotech-
nology Information.Materials and methods
Cell lines
Two human CC cell lines (C14/KMUH, C51/KMUH) estab-
lished by our institution were investigated. The detailed
methodology for the establishment of these cell lines was
described in our previous study [15]. These cell lines
were verified using positive for periodic acid-Schiff stain
and stain for cytokeratin 19 but negative for monoclonal
mouse antihuman hepatocyte antigen. All procedures to
establish these cell lines were approved by the Institu-
tional Review Board of our hospital, and patients
provided informed consent. All cultures were maintained
at 37C in a humidified atmosphere of 5% CO2 and 95% air.
The serum-containing culture medium consisted of 10%
fetal bovine serum, 90% Dulbecco Modified Eagle
high glucose medium, supplemented with 20mM L-gluta-
mine, 100 U/mL penicillin, and 100 mg/mL
streptomycin (HyClone, Logan, Utah, USA). Colchicine
was purchased from Sigma-Aldrich Corporate (St. Louis,
MO, USA).Proliferative experiment
Each cell line seeded in a 96-well culture plate was
incubated with serum-containing medium for 24 hours.
Next, the medium was replaced with serum-free medium
with various concentrations of colchicine (0 ng/mL, 2 ng/
mL, and 6 ng/mL). The cells were incubated for an addi-
tional 72 hours for proliferative assay. The premixed WST-
1 cell proliferation reagent (Clontech Laboratories, Inc., A
Takara Bio Company, Mountain View, CA, USA) was
applied. The principle for this examination is that the
stable tetrazolium salt WST-1 is cleaved to a soluble for-
mazan by viable cells. The amount of formazan dye
formed detected by the spectrophotometer expressed as
optical density directly correlates to the number of
metabolically active cells in the culture. The experi-
mental procedures were carried out following the manu-
facturer’s protocols. The cells were incubated with
reagent for 3 hours at 37C in a humidified atmosphere of
5% CO2 and 95% air. Then, the results were analyzed using
an automated microplate reader (MRX, Dynex Technolo-
gies, Inc., Chantilly, VA, USA). Absorbance was measured
at a wavelength of 450 nm (reference wavelength
630 nm). In all experiments, 16 replicate wells were used
for statistical calculation.
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polymerase chain reaction experiments
Each cell line was seeded in three 25-cm2 plastic culture
flasks with serum-containing medium for 24 hours. Then,
the medium was replaced with serum-free medium with
various concentrations of colchicine (0 ng/mL, 2 ng/mL,
6 ng/mL). The cells were incubated for a further 24 hours.
Total RNA in each flask was extracted using Trizol Reagent
(Invitrogen, Life Technologies Corporation, Grand Island,
NY, USA), and followed by RNAeasy Mini Kit (QIAGEN
GmbH, Hilden, Germany). Purified RNA was quantified by
OD260 nm using a ND-1000 spectrophotometer (Nanodrop
Technology, Wilmington, DE, USA) and qualified using
Bioanalyser 2100 (Agilent Technologies, Santa Clara, CA,
USA). To investigate genes with consistently differential
expressions caused by different concentrations of colchi-
cine, two microarrays (Agilent SurePrint G3 Human GE
8  60 k, Agilent Technologies) were applied for C14/
KMUH (6 ng/mL colchicine vs. control without colchicine)
and C51/KMUH (6 ng/mL colchicine vs. control 2 ng/mL
colchicine) cells, respectively. Microarray experimental
procedures were carried out following the manufacturer’s
protocols and the criteria for the selection of differen-
tially expressed genes were the same as in our previous
studies [16,17]. For quantitative reverse transcription-
polymerase chain reaction (RT-PCR) study, specific oligo-
nucleotide primer pairs were selected from RocheFigure 1. Antiproliferative effects of colchicine on two
human cholangiocarcinoma cell lines (C14/KMUH and C51/
KMUH). The premixed WST-1 cell proliferation reagent was
applied for investigation. The absorbance was measured at a
450-nm wavelength (reference wavelength 630 nm). In all ex-
periments, 16 replicate wells were used to determine the
mean and the standard deviation (SD). The unpaired two-tailed
t test was applied for statistical analysis. Bars indicate SD. a, b,
c, d, e, f: p < 0.0001. a, d: 2 ng/mL colchicine versus control;
b, e: 6 ng/mL colchicine versus control; c, f: 6 ng/mL colchi-
cine versus 2 ng/mL colchicine.Universal ProbeLibrary (Roche Diagnostics Ltd., Taipei,
Taiwan). The procedures for real-time PCR reactions and
the calculation of the fold expression or repression of the
target gene were the same as in our previous studies
[16,17]. The housekeeping gene TBP (TATA box binding
protein) was used as a reference gene. Two genes were
selected for quantitative RT-PCR study. The PCR primers
used were 50-CTTCAAGACAGAGTCAGTGAGAAAC-30 sense
primer and 50-CCAGGCGTAGCGAGTGC-30 antisense primer
for HSD11B2, 50-AGCAGGAACAGGTTGAACAGTC-30 sense
primer and 50-AGGAGAAGATGGTTAGGTCTACGG-30 anti-
sense primer for MT-COI, and 50-CAATTTAGTAGTTAT-
GAGCCAGAG-30sense primer and 50-TTCTGCTCT
GACTTTAGCAC-30 antisense primer for TBP.Nude mouse experiment
This study was approved by the Institutional Animal Care
and Use Committee of Kaohsiung Medical University
(Kaohsiung, Taiwan). All mice were kept in the Experi-
mental Animal Center of our hospital. The feeding pro-
cess was carried out by a qualified staff member using a
syringe connected with a feeder. Fourteen male nude
mice (BALB/c-nu) purchased from The Taiwan Laboratory
Animal Center of National Health Research Institutes,
Taipei City, Taiwan were equally divided into the control
and two treatment groups. A total of 5  106 C14/KMUH
cancer cells suspended in 0.2 mL serum-containing cul-
ture medium were injected subcutaneously into the flank
of each mouse. When tumors reached a diameter of
4e5 mm in the largest dimension, each mouse in the
treatment group was continuously fed with 0.07 mg
colchicine/kg dissolved in phosphate-buffered saline
once/d for 14 days. All mice were sacrificed at the 15th
day after the start of colchicine treatment. The tumor
volumes were calculated using the formula:
length  width2  0.5 [18]. The increased tumor volume
ratio was calculated as follows: tumor volume at day x
(Vx) divided by baseline pretreatment tumor volume
(V0).The tumor growth rates were calculated using the
formula: ln(V0eV14)/(t0t14), where V0 and V14 are tumor
volumes at the start of treatment and at the 14th day of
treatment, respectively, and t is the day for the mea-
surement of tumor volume [19]. All tumors were imme-
diately fixed in 24% formalin after sacrifice of the mice.
Then, all tumors were embedded in paraffin within 24
hours for further pathological study. Serial sections at a
distance of 3 mm for all tumors were performed to detect
the percentage of tumor necrosis.Statistical analysis
Statistical analysis was performed using GraphPad Prism
software version 4.03 (GraphPad Software, Inc., La Jolla,
CA, USA). Results are given as mean values  standard
deviations (SD) or standard errors of the mean. An unpaired
two-tailed t test was used to analyze the significance of any
difference between two means. Statistical significance was
defined as p < 0.05.
232 C.-C. Wu et al.Results
Proliferative experiment
Colchicine significantly inhibited the cellular proliferation
of both cell lines (Fig. 1). The antiproliferative effects of
colchicine on both cell lines were dose-dependent. The
inhibitory effects of 2 ng/mL and 6 ng/mL colchicine on
cellular proliferation were: (1) 23.2% and 57.2% for C14/
KMUH cells; and (2) 25.6% and 57.1% for C51/KMUH cells,
respectively.
Microarray and quantitative RT-PCR analyses
Colchicine at a concentration of 6 ng/mL caused upregu-
lations of nine genes (ASAP1-IT1, CCDC40, KIAA0485,
LOC401497, MAGI2-IT1, MGC24103, ODF3L1, RN7SL1, and
TAF15) and downregulations of 21 genes (ACTRT2, AOC2,
C1QTNF5, DLGAP1-AS2, DUSP9, ECEL1P2, EFCC1, GRHL3,
HLA-DPB2, HSD11B2, LOC100129620, LOC100509378,
LOC399900, MAGEE1, MT-COI, RASL10B, SPPL2B, TMEM50B,
TNXB, TRIM58, and ZNF687) in C14/KMUH cells compared
with the control without colchicine. Six genes (CREB5,
GAS7, RRAD, TPPP, TPPP3, and UBE2E1) were upregulated
and 12 genes (ACTRT2, C17orf74, C1QTNF5, C9orf106,
CNGA1, ECEL1P2, GJA9, HLA-DPB2, HSD11B2,
LOC100129620, MAGEE1, and MEIOB) were downregulated
caused by 6 ng/mL colchicine in C51/KMUH cells compared
with 2 ng/mL colchicine. Seven genes (ACTRT2, C1QTNF5,
ECEL1P2, HLA-DPB2, HSD11B2, LOC100129620, and
MAGEE1) were consistently downregulated caused by
different concentrations of colchicine in both cell lines.
There was no consistently upregulated gene caused by
different concentrations of colchicine in both cell lines.
Among those differentially expressed genes detected by
microarray, two genes (HSD11B2 and MT-COI ) were
selected for further quantitative RT-PCR analysis. The
reason for this selection was that differential expressions of
these genes could contribute to the anticancer effects of
colchicine on CC. There was a good consistency between
results from quantitative RT-PCR and microarray. The re-
sults of quantitative RT-PCR were shown in Table 1. Both
2 ng/mL and 6 ng/mL colchicine caused downregulations of
both HSD11B2 and MT-COI in the C14/KMUH cell line butTable 1 Gene expression fold change caused by colchi-
cine in two human cholangiocarcinoma cell lines.
Gene name HSD11B2 MT-COI
Colchicine (ng/mL) 2/0a 6/0 6/2 2/0 6/0 6/2
C14/KMUH 0.57 0.54 0.96 0.15 0.20 1.29
C51/KMUH 1.06 0.67 0.62 0.84 0.91 1.08
Gene expression fold change was determined using quantitative
reverse transcription-polymerase chain reaction. The house-
keeping gene TBP (TATA box binding protein) was used as the
reference gene. The value of gene expression fold change  1.3
was defined as upregulation and  0.7 was defined as
downregulation.
a Colchicine concentration used in experimental cells/
colchicine concentration used in control cells.these effects were not dose-dependent. Colchicine caused
downregulation of HSD11B2 in C51/KMUH cells only at a
concentration of 6 ng/mL. Both 2 ng/mL and 6 ng/mL
colchicine had no influence on expression of MT-COI in C51/
KMUH cells.
Nude mouse experiment
All the mice survived. The control mice significantly gained
more body weight than colchicine-treated mice during the
experimental period (2.43  0.05 g vs. 1.33  0.33 g,
p < 0.005). The increased tumor volume ratios in
colchicine-treated mice were significantly lower than con-
trol mice started from the 11th day of treatment
(pZ 0.0167; Fig. 2). The tumor growth rates in colchicine-
treated mice after 14 days of treatment were also signifi-
cantly lower than control mice (0.147  0.004/d vs.
0.274  0.003/d, pZ 0.0015). Pathological analysis showed
that control mice had significantly larger percentages of
tumor necrotic areas than colchicine-treated mice
(44.3  5.3% vs. 31.7  7.5%, p Z 0.0075).Discussion
The current study showed that the clinically acceptable
colchicine concentrations had significantly dose-dependent
antiproliferative effects on CC. These effects were similar
to those observed in HCC cells as demonstrated in our
previous study [14]. This can be explained by the direct
colchicineetubulin interaction to perturb the assembly
dynamics of microtubules as a common anticancer mecha-
nism in both CC and HCC cells [6e10]. However, the effects
of colchicine on differential expressions of genes thatFigure 2. Increased tumor volume ratios in colchicine-
treated and control mice. The increased tumor volume
ratio Z Vx/V0 (Vx: tumor volume at day x, V0: baseline pre-
treatment tumor volume). Data are expressed as mean
values  standard errors of the mean (error bars). The
increased tumor volume ratios in colchicine-treated mice were
significantly lower than control mice started from the 11th day
of treatment. a: p Z 0.0167, b: p Z 0.0062, unpaired t test.
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cells were not the same. The effects of colchicine on the
dose-dependent upregulations of two antiproliferative
genes (AKAP12 and TGFB2) in HCC cells [14] were not
observed in CC cells. HSD11B2, which was downregulated
by colchicine in cancer-associated fibroblasts but not in
HCC cells [14], was also downregulated by 6 ng/mL
colchicine in both CC cell lines and by 2 ng/mL colchicine in
the C14/KMUH cell line. The protein encoded by HSD11B2 is
a type II isozyme of the corticosteroid 11-beta-dehydroge-
nase that catalyzes cortisol to the inactive metabolite
cortisone. This protein prevents illicit activation of the
mineralocorticoid receptor in tissues with expression of
mineralocorticoid receptor, and protects cells from the
growth-inhibiting and/or proapoptotic effects of cortisol in
tissues without expression of the mineralocorticoid recep-
tor [20,21]. Downregulation of HSD11B2 can contribute to
the anticancer effects of colchicine on CC cells. For C14/
KMUH cells, colchicine also caused downregulation of MT-
COI to enhance the anticancer effects of colchicine on
these cells. The protein encoded by MT-COI known as cy-
tochrome c oxidase subunit I is one of three mitochondrial
DNA encoded subunits of respiratory complex IV. Complex
IV is the final enzyme of the electron transport chain of
mitochondrial oxidative phosphorylation. It plays a crucial
role in the regulation of aerobic production of cellular en-
ergy to drive all cellular processes [22,23]. Dysfunction of
cytochrome c oxidase not only will impair cellular energy
supply but also can increase mitochondrial reactive oxygen
species production and cellular toxicity [22,23].
Different concentrations of colchicine also caused dif-
ferential expressions of several genes, which may favor CC
progression. These include upregulation of TAF15 and
downregulations of DUSP9, GRHL3, and RASL10B in C14/
KMUH cells and upregulation of RRAD in C51/KMUH cells.
The protein encoded by TAF15 plays a role in RNA poly-
merase II gene transcription. Upregulation of TAF15 can
promote cellular proliferation [24]. The protein encoded by
DUSP9 is a member of the mitogen-activated protein kinase
phosphatases that act as negative regulators of mitogen-
activated protein kinase activity in mammalian cells.
DUSP9 expression can cause microtubule disruption [25]
and may be a tumor suppressor [25]. GRHL3 encodes a
member of the Grainyhead family of transcription factors.
Decreased GRHL3 expression has been reported to
contribute to tumor progression in squamous cell carci-
noma of the skin [26]. The protein encoded by RASL10B is a
new member of Ras superfamily with tumor suppressor
potential [27]. The protein encoded by RRAD is a Ras-
related GTPase that promotes cell growth by accelerating
cell cycle transitions. Knockdown of RRAD expression can
induce cell cycle arrest and premature senescence without
additional cellular stress in multiple cancer cell lines
[28,29]. Nevertheless, our animal study showed that the
possible effects caused by differential expressions of the
aforementioned genes to promote CC progression could be
overcome by the direct colchicineetubulin interaction and
concomitantly differential expressions of genes to inhibit
proliferation of CC cells. However, two genes
(LOC100129620 and MAGEE1) were consistently down-
regulated caused by different concentrations of colchicine
in both cell lines. The functions of these commonlydownregulated genes caused by colchicine are still un-
known and need to be further investigated.
The pathological results from the nude mouse study
showed that control group had larger tumor necrotic areas
than the experimental group. Rapid proliferation of cancer
cells exceeds the speed of neovasculization for sufficient
blood supply in the control group is the explanation. This
phenomenon is similar to clinically observed spontaneous
tumor lysis syndrome in solid tumors [30]. The significant
increase of body weight in the control group was caused by
rapid increase of tumor mass in this group.
In conclusion, clinically acceptable colchicine concen-
trations have significantly dose-dependent antiproliferative
effects on CC. This drug has good potential for the pallia-
tive treatment of CC due to its low cost and our long-time
prescription experience.References
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